Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

End of Year Sale!
Grab Our Small Cap Recommendation
Service at a 60% Discount




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets open firm
Mon, 26 Dec 09:30 am

Asian stock markets have opened the day on a mixed note with stock markets in Japan (up 1.1%) trading in the green. However, markets in South Korea (down 0.3%) and China (down 0.3%) are facing selling pressure. The Indian stock markets have opened the day on a firm note. Stocks in the technology, realty and capital goods space are leading the gains.

The BSE-Sensex is trading higher by 90 points (0.6%), while the NSE-Nifty is up by around 26 points (0.6%). Mid cap and small cap stocks are trading in the green as well, with the BSE Mid Cap and BSE Small Cap indices up by 0.6% each. The rupee is trading at 52.89 to the US dollar.

Indian Pharma stocks have opened the day on a mixed note with Ranbaxy Laboratories and Biocon trading in the red. However, Aurobindo Pharma and IPCA Labs are trading firm. Leading pharma company, Lupin, is planning to replicate the business model of its Japanese subsidiary in other countries. In Japan, Lupin has been expanding through acquisitions in the local market. Recently, the company acquired I'rom Pharmaceuticals and now aims to have US$ 300 m revenues from the Japanese market. To further strengthen its global operations, Lupin aims at a similar acquisition strategy in America, Europe, and Canada. It will concentrate first in the markets like Brazil, Argentina, and some European countries. At present in Brazil, the company has a strategic tie-up with the state-run company to market its products. In Argentina, Lupin sells through third party distributors approved by World Health Organisation (WHO).

Auto stocks have opened the day on a firm note with Exide Industries, Tata Motors, Ashok Leyland, Hero MotoCorp and Mahindra & Mahindra (M&M) trading in the green. M&M has signed a Memorandum of Understanding (MoU) with public sector lender Indian Overseas Bank (IOB) for providing financing for a range of its vehicles. IOB had plans to enter commercial vehicle financial market and through this MoU it has done so. The bank offers financing of commercial vehicles at 12.5% interest rate. As per a certain senior personnel of M&M, the automaker was growing at 20% year-on-year (YoY) in the passenger vehicle space and at 35-40% in the commercial vehicle space.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.